Enfortumab vedotin is an antibody-drug conjugate targeting Nectin-4, a protein highly expressed in urothelial carcinoma. Nearly 90% of all the types of bladder cancer accounts for urothelial cancer, the most common bladder cancer reported in the US. The most commonly reported symptoms of urothelial cancer are haematuria, pelvic pain accompanied by